SCHEDULE 13D/A Filed 2026-07-07 Event 2026-07-02 SEC 0001346824-26-000189 →

RA CAPITAL MANAGEMENT, L.P. → Climb Bio, Inc. CLYM

Stake: 33.00% Shares: 23,249,186 CUSIP: 28658R106 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

Item 4 of the Statement is hereby amended and supplemented as follows: On June 29, 2026 Dr. Breanna Celebi (O'Reilly), an Analyst of RA Capital, was appointed to the Board of Directors of the Issuer as the designee of RA Capital, replacing Dr. Andrew Levin, who resigned from the Board of Directors effective June 29, 2026.

Cross-References

Insider Activity (last 365d)

2 transactions

0 buys · 1 sales · 1 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

86 filings by this filer

85 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 5.64

9,718,558 shares short · +14.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $2.87M

Point72 Asset Mgmt

Post-Filing Returns · since 2026-07-02 on CLYM

+1 day

+2.9%

+5 days

+4.0%

+30 days

—

+60 days

—

+90 days

—

+180 days

—

Anchor price 12.90 on closest trading day on/after 2026-07-02. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-29	Brennan Aoife	director, officer	Sale	30,902	$13.17	$407K
2026-06-27	Brennan Aoife	director, officer	Option exercise	68,750	—	—

Other 13D/G Filings on Climb Bio, Inc.

Filed	Form	Filer	Stake	Shares
2026-07-08	SCHEDULE 13G	FMR LLC	—	—	view →
2024-07-01	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →
2024-03-18	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2026-09-22	SCHEDULE 13G	BetterLife Pharma Inc.	—	—	view →
2026-09-21	SCHEDULE 13D/A	SIONNA THERAPEUTICS, INC.	14.30%	6,476,193	view →
2026-09-17	SCHEDULE 13D/A	TYRA BIOSCIENCES, INC.	—	14,130,492	view →
2026-09-03	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →
2026-06-15	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	5,138,703	view →
2026-06-15	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC. ARTV	36.60%	17,811,623	view →
2026-06-03	SCHEDULE 13G	Editas Medicine, Inc. EDIT	—	—	view →

Showing 20 of 85

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →